Vernalis is pleased to announce the achievement of the second milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). Vernalis will receive a payment of £0.5m in recognition of this achievement.
This collaboration with AKP was initiated in October 2013 and utilises Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid arthritis and other autoimmune diseases. Overall financial terms of this collaboration have not been disclosed.